866-997-4948(US-Canada Toll Free)

Diabetic Neuropathy - Pipeline Review, H2 2012

Published By :

Global Markets Direct

Published Date : Sep 2012

Category :

Diabetes

No. of Pages : 92 Pages


Global Markets Directs, \'Diabetic Neuropathy - Pipeline Review, H2 2012\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Diabetic Neuropathy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Diabetic Neuropathy. 

Diabetic Neuropathy - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Diabetic Neuropathy.
  • A review of the Diabetic Neuropathy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. 
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Diabetic Neuropathy pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Diabetic Neuropathy.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. 
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Diabetic Neuropathy pipeline depth and focus of Indication therapeutics. 
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. 
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Diabetic Neuropathy Overview 9
Therapeutics Development 10
An Overview of Pipeline Products for Diabetic Neuropathy 10
Diabetic Neuropathy Therapeutics under Development by Companies 12
Diabetic Neuropathy Therapeutics under Investigation by Universities/Institutes 14
Late Stage Products 15
Comparative Analysis 15
Mid Clinical Stage Products 16
Comparative Analysis 16
Pre-Clinical Stage Products 17
Comparative Analysis 17
Diabetic Neuropathy Therapeutics Products under Development by Companies 18
Diabetic Neuropathy Therapeutics Products under Investigation by Universities/Institutes 19
Companies Involved in Diabetic Neuropathy Therapeutics Development 20
Daiichi Sankyo Company, Ltd 20
Merck & Co., Inc. 21
Dainippon Sumitomo Pharma Co., Ltd. 22
Takeda Pharmaceutical Company Limited 23
Dong-A Pharmaceutical Co., Ltd. 24
Lpath, Inc. 25
NeurogesX, Inc. 26
Diamyd Medical AB 27
R-Tech Ueno, Ltd. 28
Neurotune AG 29
Arcion Therapeutics, Inc. 30
Taiwan Liposome Company 31
Viromed Co., Ltd. 32
Cebix Incorporated 33
TheraQuest Biosciences, LLC 34
Beech Tree Labs, Inc. 35
Diabetic Neuropathy Therapeutics Assessment 36
Assessment by Monotherapy Products 36
Assessment by Combination Products 37
Assessment by Route of Administration 38
Assessment by Molecule Type 40
Drug Profiles 42
ranirestat - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
ranirestat - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
TAK-428 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Lpathomab - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
iroxanadine - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
NT-13317 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
NG2-GAD - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
tapentadol hydrochloride ER - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
capsaicin - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
VM-202 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
RTU-1096 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Allopurinal + Alpha Lipoic Acid + Nicotinamide - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
clonidine hydrochloride - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Cannabis Based Medicine Extract - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
DA-3030 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
MK-6096 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
alprostadil - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
Vascular Endothelial Growth Factor - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
Drug For Neuropathy - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
DS-5565 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
mepivacaine - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
NT-24336 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
Ersatta - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
DA-9801 - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
Rosuvastatin - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
Diabetic Neuropathy Therapeutics Drug Profile Updates 76
Diabetic Neuropathy Therapeutics Discontinued Products 83
Diabetic Neuropathy Therapeutics - Dormant Products 84
Diabetic Neuropathy Product Development Milestones 85
Featured News & Press Releases 85
Aug 29, 2012: RegeneRx Reports That Thymosin Beta 4 Promotes Recovery Of Peripheral Neuropathy In Type II Diabetic Mice 85
Jun 09, 2012: Cebix\'s Ersatta Demonstrates Encouraging Results In Phase I Study Of Diabetic Peripheral Neuropathy 85
May 04, 2012: Pfizer Reports Top-Line Results From Phase III Trial Of Lyrica Capsules CV In Patients With Diabetic Peripheral Neuropathy 86
Mar 20, 2012: Astellas Pharma Europe Withdraws Its Applications For Extension Of Indication For Qutenza 86
Feb 21, 2012: SK Biopharmaceuticals Initiates Phase II Trials In US 87
Nov 07, 2011: NephroGenex Reaches Agreement With FDA On Subpart H Phase III Program For Pyridorin 87
Oct 31, 2011: J&JPRD Submits Supplemental New Drug Application To FDA For NUCYNTA ER Tablets For Diabetic Peripheral Neuropathic Pain 88
Oct 19, 2011: Concert Pharmaceuticals To Present Data On CTP-499 At American Society of Nephrology Kidney Week Meeting 88
Oct 11, 2011: Antisense Completes Dosing In ATL1103 Phase I Clinical Trial 89
Sep 12, 2011: Spinifex Pharmaceuticals Presents New Data On EMA401 In Model Of Diabetic Neuropathy At 21st Annual NEURODIAB Meeting 90

Appendix 91
Methodology 91
Coverage 91
Secondary Research 91
Primary Research 91
Expert Panel Validation 91
Contact Us 92
Disclaimer 92

List of Table


Number of Products Under Development for Diabetic Neuropathy, H2 2012 10
Products under Development for Diabetic Neuropathy Comparative Analysis, H2 2012 11
Number of Products under Development by Companies, H2 2012 13
Number of Products under Investigation by Universities/Institutes, H2 2012 14
Comparative Analysis by Late Stage Development, H2 2012 15
Comparative Analysis by Mid Clinical Stage Development, H2 2012 16
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 17
Products under Development by Companies, H2 2012 18
Products under Investigation by Universities/Institutes, H2 2012 19
Daiichi Sankyo Company, Ltd, H2 2012 20
Merck & Co., Inc., H2 2012 21
Dainippon Sumitomo Pharma Co., Ltd., H2 2012 22
Takeda Pharmaceutical Company Limited, H2 2012 23
Dong-A Pharmaceutical Co., Ltd., H2 2012 24
Lpath, Inc., H2 2012 25
NeurogesX, Inc., H2 2012 26
Diamyd Medical AB, H2 2012 27
R-Tech Ueno, Ltd., H2 2012 28
Neurotune AG, H2 2012 29
Arcion Therapeutics, Inc., H2 2012 30
Taiwan Liposome Company, H2 2012 31
Viromed Co., Ltd., H2 2012 32
Cebix Incorporated, H2 2012 33
TheraQuest Biosciences, LLC, H2 2012 34
Beech Tree Labs, Inc., H2 2012 35
Assessment by Monotherapy Products, H2 2012 36
Assessment by Combination Products, H2 2012 37
Assessment by Stage and Route of Administration, H2 2012 39
Assessment by Stage and Molecule Type, H2 2012 41
Diabetic Neuropathy Therapeutics Drug Profile Updates 76
Diabetic Neuropathy Therapeutics Discontinued Products 83
Diabetic Neuropathy Therapeutics Dormant Products 84

List of Chart


Number of Products under Development for Diabetic Neuropathy, H2 2012 10
Products under Development for Diabetic Neuropathy Comparative Analysis, H2 2012 11
Products under Development by Companies, H2 2012 12
Products under Investigation by Universities/Institutes, H2 2012 14
Late Stage Products, H2 2012 15
Mid Clinical Stage Products, H2 2012 16
Pre-Clinical Stage Products, H2 2012 17
Assessment by Monotherapy Products, H2 2012 36
Assessment by Combination Products, H2 2012 37
Assessment by Route of Administration, H2 2012 38
Assessment by Stage and Route of Administration, H2 2012 39
Assessment by Molecule Type, H2 2012 40
Assessment by Stage and Molecule Type, H2 2012 41

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *